Get the Stockscreener App
0.2021
1.00%
0.002
Pre-market:
.20
-0.0021
-1.04%
VolitionRX Ltd stock is traded at $0.2021, with a volume of 1.21M.
It is up +1.00% in the last 24 hours and down -22.24% over the past month.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
See More
Previous Close:
$0.2001
Open:
$0.203
24h Volume:
1.21M
Relative Volume:
0.56
Market Cap:
$27.40M
Revenue:
$1.47M
Net Income/Loss:
$-23.06M
P/E Ratio:
-0.8887
EPS:
-0.2274
Net Cash Flow:
$-19.64M
1W Performance:
-16.90%
1M Performance:
-22.24%
6M Performance:
-68.17%
1Y Performance:
-67.40%
1-Day Range:
$0.1945
$0.2095
1-Week Range:
$0.19
$0.257
52-Week Range:
$0.17
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
Name
VolitionRX Ltd
Sector
Industry
Phone
646 650 1351
Address
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.2021 | 27.13M | 1.47M | -23.06M | -19.64M | -0.2274 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | H.C. Wainwright | Buy |
| Feb-01-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-17-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-10-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-18 | Initiated | Maxim Group | Buy |
| May-14-18 | Reiterated | The Benchmark Company | Buy |
| Sep-07-16 | Reiterated | Rodman & Renshaw | Buy |
| Feb-01-16 | Initiated | Rodman & Renshaw | Buy |
View All
VolitionRX Ltd Stock (VNRX) Latest News
Tax withholding on VolitionRx (VNRX) shares for officer via RSU settlement - Stock Titan
VolitionRx (VNRX) CCO covers tax bill via 2,283-share cancellation - Stock Titan
Tax withholding trims VolitionRx (VNRX) GC Nicholas Plummer’s shares - Stock Titan
VNRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VolitionRx issues shares to satisfy debt obligations and completes private placement - Investing.com
VNRX SEC FilingsVolitionrx 10-K, 10-Q, 8-K Forms - Stock Titan
VolitionRx (VNRX) grants CCO 149,000 RSUs in lieu of cash pay - Stock Titan
Ethel Rubin receives 178,000 RSU award at VolitionRx Ltd (VNRX) - Stock Titan
Executive at VolitionRx (VNRX) awarded 142,000 RSUs in lieu of cash pay - Stock Titan
VOLITIONRX (VNRX) CFO awarded 202,000 RSUs in lieu of cash pay - Stock Titan
119,000 RSUs granted to VolitionRx (VNRX) secretary in lieu of cash pay - Stock Titan
VolitionRx (VNRX) grants 187,000 RSUs to General Counsel Plummer - Stock Titan
[Form 4] VOLITIONRX LTD Insider Trading Activity - Stock Titan
VolitionRx (VNRX) executive receives 173,000 RSUs instead of cash pay - Stock Titan
VolitionRx (VNRX) grants CSO 149,000 RSUs instead of cash - Stock Titan
Director at VolitionRx (VNRX) granted 178,000 RSUs in lieu of cash - Stock Titan
VolitionRx advances cancer tests, expects French reimbursement By Investing.com - Investing.com India
VolitionRx Reports Clinical and Commercial Progress Across Cancer Detection and Sepsis Monitoring Platforms - citybuzz -
VolitionRx advances cancer tests, expects French reimbursement - Investing.com
Simple blood test finds most cat lymphomas, unlocks $5M for VolitionRx - Stock Titan
VolitionRx issues shares to satisfy debt and completes private placement - Investing.com Australia
VolitionRx (NYSE: VNRX) issues shares to repay Lind note - Stock Titan
VolitionRx issues shares to satisfy debt and completes private placement By Investing.com - Investing.com Canada
Q3 2025 VolitionRX Ltd Earnings Call Transcript - GuruFocus
Should You Buy VolitionRX Ltd (VNRX) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Armistice Capital reports 4.99% stake in VolitionRx (VNRX) — 6.45M shares - Stock Titan
Guidance Update: Is VolitionRx Limited gaining market share2025 Trading Volume Trends & Weekly Watchlist of Top Performers - baoquankhu1.vn
Volume Summary: Is now the right time to enter VolitionRx LimitedJuly 2025 Retail & Step-by-Step Trade Execution Guides - mfd.ru
VolitionRx nears 100 Nu.Q Discover clients, extends reach to Japan - Stock Titan
Volition Announces the Appointment of New Distributor for Nu.Q® Discover - Finansavisen
VolitionRx receives NYSE American non-compliance notice By Investing.com - Investing.com Australia
VolitionRx (VNRX) Plans to Offer Nearly 18 Million Shares - GuruFocus
VolitionRx (VNRX) Faces NYSE American Compliance Challenge - GuruFocus
VolitionRx Gets NYSE American Non-Compliance Notice for Failing Equity Requirements - marketscreener.com
VolitionRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VolitionRx stock gets 'below compliance' tag after NYSE warning - Stock Titan
Volume Report: Is VolitionRx Limited affected by consumer sentimentJuly 2025 Earnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
VolitionRx Prepares French Reimbursement Submission for Nu.Q Cancer Blood Tests - MEXC
VolitionRx (VNRX) Moves Forward with French Reimbursement Submis - GuruFocus
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays - Yahoo Finance
VolitionRx moves to bring Nu.Q lung cancer test to French patients - Stock Titan
What is the cash position of VolitionRx LimitedWeekly Market Report & High Conviction Investment Ideas - mfd.ru
Aug Wrap: Is VolitionRx Limited benefiting from innovation trendsMarket Activity Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
VNRX: D. Boral Capital Maintains Buy Rating and $3 Price Target - GuruFocus
VolitionRx (VNRX) Expands Nu.Q Vet Cancer Test Reach in U.S. and Asia - GuruFocus
Dog cancer blood test expands to all 50 states and parts of Asia - Stock Titan
VolitionRX (VNRX) Receives Buy Rating, Price Target Maintained a - GuruFocus
Why VolitionRx Limited stock is popular among millennialsEarnings Growth Report & Expert Curated Trade Setups - Улправда
VolitionRx Signs Amended Securities Purchase Agreement With Lind Global Asset Management XII - TradingView — Track All Markets
Is VolitionRx Limited stock trading near support levels2025 Key Lessons & Growth Oriented Trading Recommendations - Улправда
Volitionrx stock soars after feline cancer test shows high accuracy By Investing.com - Investing.com Nigeria
VolitionRX Ltd Stock (VNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):